Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate - Concepedia

Concepedia

Publication | Open Access

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

DOI Full Paper Access

394

Citations

23

References

2010

Year

Alison Reid, Gerhardt Attard, Daniel C. Danila, Nikhil Babu Oommen, David Olmos, Peter C.C. Fong, L. Rhoda Molife, Joanne Hunt, Christina Messiou, Christopher Parker,

Journal of Clinical Oncology

Abstract

Abiraterone acetate has significant antitumor activity in post-docetaxel patients with CRPC. Randomized, phase III trials of abiraterone acetate are underway to define the future role of this agent.

References

	Year	Citations

Page 1